well wrong. $57 M is a drop in the bucket and it removes all uncertainty. It's even better as it seems to cover all marketed products for the said time period.
take a look at both BP and RIG - how their stock reacted when their settlement amounts were announced. Markets don't like uncertainties hanging over a co's head - now it's behind - at a cheap rate at that.
I don;t consider a 30% hit to quarterly earnings a drop in the bucket, but I agree it is preferable not to be facing litigation. Investors in pharma companies always face high uncertainties given the ongoing risks to new drug developments. It's all part of the game.